Researchers discuss HER2-low and HER2-zero in breast cancer
A new editorial paper titled "HER2-low and HER2-zero in breast cancer between prognosis, prediction and entity" has been published in Oncotarget.
Jul 16, 2024
0
0
A new editorial paper titled "HER2-low and HER2-zero in breast cancer between prognosis, prediction and entity" has been published in Oncotarget.
Jul 16, 2024
0
0
A new meta-analysis published in OMICS: A Journal of Integrative Biology helps shed light on how changes in mitochondria-related gene expression may cause the cardiotoxicity associated with the cancer therapy trastuzumab.
Mar 18, 2024
0
0
For patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer previously treated with trastuzumab and a taxane, the risk of progression or death from any cause is lower with trastuzumab ...
Mar 24, 2022
0
6
Treating women diagnosed with one type of early-stage breast cancer with the monoclonal antibody trastuzumab after surgery reduces the risk of the cancer returning, reports a research team led by University of Saskatchewan ...
Jan 31, 2022
0
54
A moderate amount of a peptide-enhanced, biological cancer drug goes a long way in treating breast cancers that metastasize to the bone.
Jan 24, 2022
0
76
The NRG Oncology clinical trial NRG-RTOG 1010, studying the addition of the drug trastuzumab to chemoradiation and surgery, did not reach its primary goal of improving disease-free survival (DFS) rates for patients with HER2 ...
Jan 21, 2022
0
15
During the virtual 2021 Annual Congress of the European Society for Medical Oncology (ESMO), 16-21 September, research (co) led by VHIO investigators revealed promising advances in the treatment of metastatic breast cancer. ...
Sep 20, 2021
0
3
Thomas Hatschek, associate professor at the department of Oncology-Pathology, together with colleagues, has recently published an article in JAMA Oncology showing that a new treatment for breast cancer with an antibody linked ...
Aug 18, 2021
0
337
Yale Cancer Center (YCC) scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive form of endometrial cancer. These results ...
Jun 29, 2020
0
2
A new study published in Oncotarget reports that despite relevant medical advancements, metastatic breast cancer remains an incurable disease.
Jun 4, 2020
0
1